News
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...
Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s ...
The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research. Gain access to 1:1 time with leaders in TIGIT development, and take away tangible learnings with dedicated ...
BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...
Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...
Analysts suggest that the expectations for anti-TIGIT therapies are already factored into Arcus’s stock price, with the HIF-2alpha program now viewed as the primary value driver for the company.
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...
Q2 2025 Earnings Call Transcript August 14, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1 ...
NK cells express inhibitory receptors (TIGIT, PD-1, NKG2A) that tumors exploit to evade immune attack, alongside activating receptors (NKG2D, DNAM-1) that promote cancer cell killing. Blocking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results